Publications by authors named "Silke Retlich"

Claim this Profile
A
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men.
Takuma Yonemura, Akiko Sarashina, Yoshifumi Tachibana, Silke Retlich, Nima Soleymanlou

Expert Opin Investig Drugs· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment.
Armin Schultz, Atef Halabi, Friedeborg Seitz, Katrien Lemmens, Hauke S Wülfrath, Silke Retlich

Expert Opin Investig Drugs· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes.
William V Tamborlane, Lori Mb Laffel, Jacques Weill, Maud Gordat, Dietmar Neubacher, Silke Retlich

Pediatr Diabetes· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.
Kyle T Baron, Sreeraj Macha, Uli C Broedl, Valerie Nock, Silke Retlich

Diabetes Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Silke Retlich, Vincent Duval, Ulrike Graefe-Mody, Christian Friedrich, Sanjay Patel

Clin Pharmacokinet· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.
Yusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, Shinji Tatami, Christian Friedrich, Silke Retlich

J Pharm Pharm Sci· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
Christian Friedrich, Stephan Glund, Dominick Lionetti, C James Kissling, Julian Righetti, Silke Retlich

Br J Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
Jorge Luiz Gross, James Rogers, Daniel Polhamus, William Gillespie, Christian Friedrich, Silke Retlich

BMJ Open· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Ulrike Graefe-Mody, Peter Rose, Silke Retlich, Arne Ring, Lisa Waldhauser

Br J Clin Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Ulrike Graefe-Mody, Silke Retlich, Christian Friedrich

Clin Pharmacokinet· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.
Sasiporn Wright, Rajendra P Singh, Silke Retlich, Ulrike Graefe-Mody, Hartmut Derendorf

Int J Clin Pharmacol Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Silke Retlich, Vincent Duval, Arne Ring, Alexander Staab, Silke Hüttner

Clin Pharmacokinet· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
Silke Retlich, Vincent Duval, Ulrike Graefe-Mody, Ulrich Jaehde, Alexander Staab

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.
Silke Retlich, Barbara Withopf, Andreas Greischel, Alexander Staab, Ulrich Jaehde

Biopharm Drug Dispos· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis